UroGen Pharma Ltd. provided revenue guidance for the full year 2022. for the year, the company expects net product revenues from Jelmyto to be in the range of $70 to $80 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.2 USD | -0.30% | -0.75% | -12.20% |
14/05 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
13/05 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.20% | 478M | |
+10.40% | 118B | |
+10.44% | 106B | |
-10.00% | 23.4B | |
-1.75% | 22.1B | |
-10.26% | 18.34B | |
-41.92% | 16.59B | |
-14.72% | 15.97B | |
+6.06% | 14.03B | |
+16.76% | 11.67B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Ltd. Provides Revenue Guidance for the Full Year 2022